ProKidney Corp Dossier
Qualitative Analysis
Business overview
ProKidney Corp. (Nasdaq: PROK) is a late clinical-stage biotechnology company pioneering the development of autologous cell therapies designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes. The company's lead product candidate is rilparencel (also known as REACT®), a first-in-class, patented disease-modifying cellular therapy manufactured from a patient's own renal progenitor cells. By expanding and purifying these cells from a standard kidney biopsy and reintroducing them via a minimally invasive percutaneous procedure, rilparencel aims to stabilize or improve the estimated glomerular filtration rate (eGFR) slope, potentially delaying or preventing the need for dialysis or transplantation.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of rilparencel (formerly REACT), an autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes.
Expected impact: Successful clinical outcomes will support a BLA submission under the FDA's accelerated approval pathway, potentially establishing a first-in-class therapy for diabetic CKD.
Establishing commercial-scale manufacturing capabilities, including the acquisition and planned buildout of a 210,000-square-foot facility in Greensboro, North Carolina.
Expected impact: Ensures sufficient commercial manufacturing capacity to meet initial market demand for rilparencel upon potential regulatory approval.
Strengthening the executive team to transition from a clinical-stage to a commercial-ready organization, highlighted by the appointments of Greg Madison as Chief Commercial Officer and Kenneth Locke as Chief Technical Officer.
Expected impact: Enhances commercial strategy, CMC (chemistry, manufacturing, and controls), and supply chain readiness ahead of pivotal clinical readouts.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired inRegen and its affiliate Twin City Bio to obtain the foundational intellectual property and technology platform for REACT (now rilparencel), which serves as ProKidney's lead product candidate.
Financial impact: Formed the core clinical asset and pipeline of ProKidney, driving all subsequent R&D activities and the company's eventual public listing.